Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CMS Should Delay PET Reassignment To New APC By One Year - AdvaMed

This article was originally published in The Gray Sheet

Executive Summary

The Centers for Medicare & Medicaid Services' decision to reassign FDG positron emission tomography (PET) to a new ambulatory payment classification (APC) in calendar 2002 does not keep pace with current uses of the imaging procedure nor with PET's increasing acceptance by clinicians, according to the device trade group AdvaMed.

You may also be interested in...



Medicare Revisits “New Technology” Outpatient Payment Levels For 2002

FDG-PET will be reimbursed at $1,375 per procedure under CMS' hospital outpatient prospective payment system update for 2002. The payment rate will go into effect April 1

Medicare Revisits “New Technology” Outpatient Payment Levels For 2002

FDG-PET will be reimbursed at $1,375 per procedure under CMS' hospital outpatient prospective payment system update for 2002. The payment rate will go into effect April 1

OPPS "New Technology" Payments Should Cover Incremental Gains - Industry

CMS' stipulation that only "truly new" procedures should be eligible for new-technology ambulatory payment classification (APC) payments is unacceptable, device manufacturers maintain.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT015533

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel